Astron Health

Astron Health is a precision oncology research company that develops bioinformatics platforms to support personalized cancer treatment. The company integrates genomic, transcriptomic, and proteomic data to improve treatment matching for cancer patients.

Astron Health applies artificial intelligence (AI) to analyze existing drug libraries and identify potential drug repurposing opportunities in oncology.

Operations

Astron Health was founded in 2024 to address limitations in conventional precision oncology, which primarily relies on genomic (DNA) testing to guide targeted cancer therapies. Research cited by the company indicates that a substantial proportion of patients with actionable genomic biomarkers do not respond to matched therapies, as genetic alterations do not always result in biologically active drug targets.

Astron Health’s scientific advisory board includes academic oncologists and clinicians such as Dr. Shivan Sivakumar, associate professor of oncology at the University of Birmingham, and Dr. D. Barry Boyd, assistant professor of medicine (medical oncology) at Yale School of Medicine and author of The Cancer Recovery Plan.

Astron Health’s methodology is informed by published research highlighting limitations of genomic-only testing, including a 2020 study showing that some tumors harbor potentially deleterious DNA mutations that are not expressed at the RNA level,  research demonstrating variable MAPK pathway activation in BRAF V600E–mutated melanoma despite identical genomic alterations and associated treatment resistance, and a 2022 study indicating that pathway-based molecular signatures may predict treatment response more accurately than mutation status alone.

Multi-omics integration

Astron Health’s platform integrates genomic, transcriptomic, and proteomic data to support treatment decision-making in oncology. Genomic analysis identifies gene mutations, transcriptomic profiling measures gene expression at the RNA level, and proteomic analysis evaluates protein abundance and activity. This multi-omics approach is intended to assess whether molecular targets are functionally active in a patient’s tumor prior to therapy selection.

Drug repurposing

The company also applies artificial intelligence to analyze published biomedical research in order to evaluate drug–target relationships and signaling pathways. According to Astron Health, its system processes data across thousands of cellular pathways and tens of thousands of drug–target pairs, enabling the identification of potential drug repurposing opportunities.

Services

Astron Health provides personalized research reports to patients through their referring oncologists, and its work has been referenced in published case studies describing integrative oncology approaches. The company offers the Polaris Research Report, which includes integrated pathway analysis using multi-omics data, AI-assisted synthesis of evidence from published biomedical literature, ranked treatment options based on molecular pathway activity, and drug–target matching across approved medications and supplements, with reports delivered under the supervision of the patient’s treating oncologist.